NCT03487055: Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 65 Years (Adult)
Location of Metastases: Bone
Additional Notes: 
Exclusions: Patients who have not completed the single dose arm at the core phase (NCT03239756); Previous or existing osteomyelitis or osteonecrosis of jaw- see trial for details

Comments are closed.

Up ↑